Citius plans two crucial trials after acquiring Leonard Meron Biosciences

5 August 2016

US specialty pharma company Citius Pharmaceuticals (OTCQB: CTXR) is to take two of its key products into trials in 2017, ambitious bosses have said as in a new article on its upcoming plans.

The company has now completed its acquisition of USA-base Leonard-Meron Biosciences for an undisclosed amount, adding a treatment for catheter-related bloodstream infections (CRBSIs) called Mino-Lok to its portfolio.

Mino-Lok joined Hydro-Lido, an experimental treatment for hemorrhoids in mid-stage development and Suprenza, a US Food and Drug Administration (FDA)-approved phentermine-based product for weight loss, but Citius decided to shelve its plans for the latter, writes the article author Sara Bowman.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK